Comprehensive Dermatologic Drug Therapy

by Stephen E Wolverton MD, Jashin J. Wu MD

Overview

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you're likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You'll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor. - Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions. - Covers the best uses for new biologic therapeutics. - Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors. - Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols. - Features a highly detailed, disease-specific index, as well as purchase information for major drugs. - Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Product Details

ISBN-13:	9780323612128
Publisher:	Elsevier Science
Publication date:	12/14/2019
Sold by:	Barnes & Noble
Format:	eBook
Pages:	858
File size:	68 MB
Note:	This product may take a few minutes to download.

Table of Contents

Part I: Introduction 1 Basic Principles of Pharmacology 2 Principles for Maximizing the Safety of Dermatologic Drug Therapy 3 Polymorphisms: Why Individual Drug Responses Vary 4 Adherence to Drug Therapy 5 Medical Decision Making Part II: Important Drug Regulatory Issues 6 The FDA Drug Approval Process 7 Pharmacovigilance: Verifying that Drugs Remain Safe 8 Drugs Taken Off the Market: Important Lessons Learned Part III: Systemic Drugs for Infectious Diseases 9 Systemic Antibacterial Agents 10 Systemic Antifungal Agents 11 Systemic Antiviral Agents 12 Systemic Antiparasitic Agents Part IV: Systemic Immunomodulatory Drugs 13 Systemic Corticosteroids 14 Methotrexate 15 Azathioprine 16 Mycophenolates 17 Cyclosporine 18 Phosphodiesterase-4 and Janus Kinase Inhibitors 19 Cytotoxic Agents 20 Dapsone 21 Antimalarial Agents 22 Systemic Retinoids Part V: Drugs Used in Conjunction with UV or Visible Light 23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities 24 Extracorporeal Photochemotherapy (Photopheresis) 25 Photodynamic Therapy Part VI: Biologic Therapeutics 26 Tumor Necrosis Factor Inhibitors 27 Interleukin 12/23 Inhibitors 28 Interleukin 17 Inhibitors 29 Interleukin 23 Inhibitors 30 Rituximab 31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others Part VII: Miscellaneous Systemic Drugs 32 Antihistamines 33 Vasoactive and Antiplatelet Agents 34 Antiandrogens and Androgen Inhibitors 35 Psychotropic Agents 36 Intravenous Immunoglobulin Therapy 37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events 38 Hedgehog Pathway Inhibitors 39 Drugs for the Skinternist 40 Miscellaneous Systemic Drugs Part VIII: Topical Drugs for Infectious Diseases 41 Topical Antibacterial Agents 42 Topical Antifungal Agents 43 Topical and Intralesional Antiviral Agents 44 Topical Antiparasitic Agents Part IX: Topical Immunomodulatory Drugs 45 Topical Corticosteroids 46 Topical Retinoids 47 Topical and Intralesional Chemotherapeutic Agents 48 Topical Calcineurin Inhibitors 49 Topical Vitamin D3 Part X: Miscellaneous Topical Drugs 50 Sunscreens 51 Therapeutic Shampoos 52 α-Hydroxy Acids 53 Chemical Peels 54 Products for the Care of Chronic Wounds 55 Agents Used for Treatment of Hyperkeratosis 56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents 57 Miscellaneous Topical Agents Part XI: Injectable and Mucosal Routes of Drug Administration 58 Local Anesthetics 59 Injectable Dermal and Subcutaneous Fillers 60 Botulinum Toxin Injections 61 Oral Mucosal Therapeutics Part XII: Major Adverse Effects From Systemic Drugs 62 Hepatotoxicity of Dermatologic Drug Therapy 63 Hematologic Toxicity of Drug Therapy 64 Drug-induced Malignancy 65 Dermatologic Drugs During Pregnancy and Lactation 66 Drug Interactions 67 Cutaneous Drug Reactions With Systemic Features Part XIII: Special Pharmacology and Therapeutics Topics 68 Informed Consent and Risk Management 69 Compounding in Dermatology 70 Dermatologic Drug Therapy in Children Appendix I Core Questions for Understanding Systemic Dermatologic Drugs Appendix II The Most Potentially Serious Drug Interactions

What People are Saying About This

From the Publisher

Trusted, up-to-date guidance in the complex area of dermatologic pharmacology

Editorial Reviews

Doody's Core Titles® 2022

"I highly recommend this book. Having this reference in the medical library will make it a snap for dermatologists to be at the top of their game."

-Patricia Wong, MD (Private Practice) Doody's Review Service: 94-4 Stars!

From the Publisher